Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Bethesda, Maryland Clinical Trials

A listing of Bethesda, Maryland clinical trials actively recruiting patient volunteers.

RESULTS

Found (24) clinical trials

Study to Evaluate the Real-world Effectiveness of Lanadelumab in Participants With Hereditary Angioedema (HAE)

This observational, prospective study aims to evaluate the real-world effectiveness of lanadelumab in participants with hereditary angioedema (HAE). Participant-reported attack diaries and patient-reported outcomes (PROs) as well as physician assessments at standard of care (SoC) visits will be used to describe HAE attack rates, treatment patterns, healthcare utilization and participant ...

Phase N/A

1.03 miles

Learn More »

This is a randomized, placebo-controlled, double-blind, crossover study of oral BTD-001 in adults with Idiopathic Hypersomnia.  

Phase

1.03 miles

Learn More »

Evaluation of the Research to Policy Collaboration Model

Objective: The aim of this study is to examine the effectiveness of a model for supporting policymakers' use of research evidence within a randomized controlled trial (RCT) employing both qualitative and quantitative analyses of survey, interview, and observational data to understand the use of research in policy and collaboration. Legislators' ...

Phase N/A

1.36 miles

Learn More »

Modulating the Hippocampal and Striatal Memory Networks With rTMS

Objective The Behavioral Neurology Unit studies the human brain systems underlying learning and adaptation with the ultimate goal of finding interventions to make these processes more efficient. We are interested in whether repetitive transcranial magnetic stimulation (rTMS) can alter functional connectivity (FC) and behavioral efficiency in two memory networks in ...

Phase N/A

1.51 miles

Learn More »

Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma

Background Multiple Myeloma (MM) is a hematologic neoplasm of the plasma cells defined by an Mprotein greater than or equal to 3.0 g/dL or bone marrow plasma cells greater than or equal to 10% and presence of end-organ disease. Although significant advances in treatment have been made in the past ...

Phase

1.51 miles

Learn More »

Repeat Peripheral Blood Stem Cell Transplantation for Patients With Sickle Cell Disease and Falling Donor Myeloid Chimerism Levels

Nonmyeloablative allogeneic peripheral blood stem cell (PBSC) transplants are currently being investigated in phase I/II trials assessing engraftment, efficacy, and toxicity at a number of transplant centers. Our ongoing protocol for patients with severe congenital anemias, particularly sickle cell disease (SCD), and an HLA-matched sibling donor has had excellent preliminary ...

Phase

1.51 miles

Learn More »

Optimizing PTCy Dose and Timing

Background Post-transplantation cyclophosphamide (PTCy) reduces rates of severe acute and chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT) and safely facilitates human leukocyte antigen (HLA)-haploidentical HCT When clinically translated, the dose (50 mg/kg) and timing (days +3 and +4) of PTCy used were partly extrapolated from murine major ...

Phase

1.51 miles

Learn More »

An Efficacy and Safety Trial of Fedratinib in Subjects With DIPSS Intermediate or High-Risk Primary Myelofibrosis Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

This is Single-Arm, Open-Label Efficacy and Safety Trial of Fedratinib in Subjects with DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High- Risk Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF), or Post-Essential Thrombocythemia Myelofibrosis (post-ET MF) and Previously Treated with Ruxolitinib. The primary objective of the study is to evaluate ...

Phase

2.91 miles

Learn More »

Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

This is a multicenter, randomized, double-blinded, controlled Phase 3 trial of cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in combination with matched placebo. The primary objective of this study is to evaluate the effect of cabozantinib in combination with nivolumab and ipilimumab ("triplet") on the duration ...

Phase

3.04 miles

Learn More »

Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple negative Breast Cancer (TNBC)

Phase

3.8 miles

Learn More »